Immunology of TLR-independent vaccine adjuvants

Current Opinion in Immunology

Volumn 21, Issue 3, 2009, Pages 339-345

  De Gregorio, Ennio ^a   D'Oro, Ugo ^a   Wack, Andreas ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; CD1D ANTIGEN; CHEMOKINE; CHITOSAN; CORD FACTOR; CRYOPYRIN; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOSOME; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; POLYGLACTIN; POLYSTYRENE; QUIL A; SAPONIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST;

ACCESSORY CELL; CELL ACTIVATION; CELL FUNCTION; CELL INTERACTION; CLINICAL TRIAL; COMPLEX FORMATION; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; EMULSION; GRANULOCYTE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INNATE IMMUNITY; MACROPHAGE; MAST CELL; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CARRIER PROTEINS; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; TOLL-LIKE RECEPTORS;

EID: 67049173026     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2009.05.003     Document Type: Review

References (69)

1. Fraser C.K., Diener K.R., Brown M.P., and Hayball J.D. Improving vaccines by incorporating immunological coadjuvants. Expert Rev Vaccines 6 (2007) 559-578
2. Hoebe K., Janssen E., and Beutler B. The interface between innate and adaptive immunity. Nat Immunol 5 (2004) 971-974
3. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
4. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20 (2002) 197-216
5. van Duin D., Medzhitov R., and Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol 27 (2006) 49-55
6. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5 (2007) 505-517
7. Malyala P., Chesko J., Ugozzoli M., Goodsell A., Zhou F., Vajdy M., O'Hagan D.T., and Singh M. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci 97 (2008) 1155-1164
8. O'Hagan D.T., Singh M., Kazzaz J., Ugozzoli M., Briones M., Donnelly J., and Ott G. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20 (2002) 3389-3398
9. Vajdy M., Selby M., Medina-Selby A., Coit D., Hall J., Tandeske L., Chien D., Hu C., Rosa D., Singh M., et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 87 (2006) 2253-2262
10. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., Scheffczik H., Ugozzoli M., Singh M., Kazzaz J., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 (2008) 552-561
11. Garcon N., Chomez P., and Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6 (2007) 723-739
12. De Gregorio E., Tritto E., and Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 38 (2008) 2068-2071
13. Lambrecht B.N., Kool M., Willart M.A., and Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21 (2009) 23-29
14. Marrack P., McKee A.S., and Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9 (2009) 287-293
15. Brewer J.M. (How) do aluminium adjuvants work?. Immunol Lett 102 (2006) 10-15
16. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 Suppl 3 (2002) S34-39
17. Hem S.L., and Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 6 (2007) 685-698
18. Morefield G.L., Sokolovska A., Jiang D., HogenEsch H., Robinson J.P., and Hem S.L. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23 (2005) 1588-1595
19. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., Hoogsteden H.C., Hammad H., and Lambrecht B.N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205 (2008) 869-882. This is a thorough study of the immune events downstream of alum administration in vivo.
20. Goto N., Kato H., Maeyama J., Shibano M., Saito T., Yamaguchi J., and Yoshihara S. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 15 (1997) 1364-1371
21. Goto N., and Akama K. Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid. Microbiol Immunol 26 (1982) 1121-1132
22. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., and Nemazee D. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314 (2006) 1936-1938
23. Nemazee D., Gavin A., Hoebe K., and Beutler B. Immunology: Toll-like receptors and antibody responses. Nature 441 (2006) E4 discussion E4
24. Li H., Nookala S., and Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 178 (2007) 5271-5276. This is the first paper to show that alum induces the production of IL-1beta in vitro through inflammasome activation.
25. •].
26. •].
27. •].
28. •] published in 2008 demonstrates that alum targets NALP3 in vitro. The requirements of NLRP3 for alum adjuvanticity have been addressed by all papers with conflicting results depending on the readout examined and on the immunization protocol used.
29. Petrilli V., Dostert C., Muruve D.A., and Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 19 (2007) 615-622
30. Dostert C., Petrilli V., Van Bruggen R., Steele C., Mossman B.T., and Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320 (2008) 674-677
31. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., Fitzgerald K.A., and Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9 (2008) 847-856. This is a very interesting study showing that alum activates NLRP3 inflammasome through the lysosomal protease Cathepsin B, released in the cytosol following phagosomal destabilization.
32. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., Singh M., O'Hagan D.T., Petrilli V., Tschopp J., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 106 (2009) 870-875. Even particles presumed inert such as PLG are inducers of inflammasome.
33. Dupuis M., Denis-Mize K., LaBarbara A., Peters W., Charo I.F., McDonald D.M., and Ott G. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 31 (2001) 2910-2918
34. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., O'Hagan D., Rappuoli R., and De Gregorio E. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 105 (2008) 10501-10506. This study shows that alum and MF59 induce a local proinflammatory environment in the muscle characterized by chemokine production and cell recruitment events.
35. Ulanova M., Tarkowski A., Hahn-Zoric M., and Hanson L.A. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69 (2001) 1151-1159
36. Sun H., Pollock K.G., and Brewer J.M. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21 (2003) 849-855
37. Rimaniol A.C., Gras G., Verdier F., Capel F., Grigoriev V.B., Porcheray F., Sauzeat E., Fournier J.G., Clayette P., Siegrist C.A., et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22 (2004) 3127-3135
38. Seubert A., Monaci E., Pizza M., O'Hagan D.T., and Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 180 (2008) 5402-5412. MF59 and alum induce chemokine production in human monocytes, macrophages, and granulocytes and promote monocyte differentiation into DCs.
39. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6 (2006) 173-182
40. Beauvillain C., Delneste Y., Scotet M., Peres A., Gascan H., Guermonprez P., Barnaba V., and Jeannin P. Neutrophils efficiently cross-prime naive T cells in vivo. Blood 110 (2007) 2965-2973
41. Culshaw S., Millington O.R., Brewer J.M., and McInnes I.B. Murine neutrophils present class II restricted antigen. Immunol Lett 118 (2008) 49-54
42. van Gisbergen K.P., Sanchez-Hernandez M., Geijtenbeek T.B., and van Kooyk Y. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med 201 (2005) 1281-1292
43. Bogoevska V., Horst A., Klampe B., Lucka L., Wagener C., and Nollau P. CEACAM1, an adhesion molecule of human granulocytes, is fucosylated by fucosyltransferase IX and interacts with DC-SIGN of dendritic cells via Lewis x residues. Glycobiology 16 (2006) 197-209
44. van Gisbergen K.P., Ludwig I.S., Geijtenbeek T.B., and van Kooyk Y. Interactions of DC-SIGN with Mac-1 and CEACAM1 regulate contact between dendritic cells and neutrophils. FEBS Lett 579 (2005) 6159-6168
45. Aleman M., de la Barrera S., Schierloh P., Yokobori N., Baldini M., Musella R., Abbate E., and Sasiain M. Spontaneous or Mycobacterium tuberculosis-induced apoptotic neutrophils exert opposite effects on the dendritic cell-mediated immune response. Eur J Immunol 37 (2007) 1524-1537
46. Morel C., Badell E., Abadie V., Robledo M., Setterblad N., Gluckman J.C., Gicquel B., Boudaly S., and Winter N. Mycobacterium bovis BCG-infected neutrophils and dendritic cells cooperate to induce specific T cell responses in humans and mice. Eur J Immunol 38 (2008) 437-447
47. Torchinsky M.B., Garaude J., Martin A.P., and Blander J.M. Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature 458 (2009) 78-82. This is an interesting study showing that the ability of apoptotic cells to activate DCs and steer T cell differentiation depends on additional factors, namely infection or presence of TLR agonist.
48. Jordan M.B., Mills D.M., Kappler J., Marrack P., and Cambier J.C. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304 (2004) 1808-1810
49. Wang H.B., and Weller P.F. Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J Leukoc Biol 83 (2008) 817-821
50. Denzel A., Maus U.A., Rodriguez Gomez M., Moll C., Niedermeier M., Winter C., Maus R., Hollingshead S., Briles D.E., Kunz-Schughart L.A., et al. Basophils enhance immunological memory responses. Nat Immunol 9 (2008) 733-742. In this study, the contribution of basophils to secondary immune responses is analyzed in detail.
51. McLachlan J.B., Shelburne C.P., Hart J.P., Pizzo S.V., Goyal R., Brooking-Dixon R., Staats H.F., and Abraham S.N. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 14 (2008) 536-541. This study provides surprising findings thus illustrate that innate immune cells can have an important role in adjuvanticity.
52. Martin-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., and Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5 (2004) 1260-1265
53. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198 (2003) 267-279
54. Nieda M., Okai M., Tazbirkova A., Lin H., Yamaura A., Ide K., Abraham R., Juji T., Macfarlane D.J., and Nicol A.J. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103 (2004) 383-389
55. Cerundolo V., Silk J.D., Masri S.H., and Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 9 (2009) 28-38
56. Guillonneau C., Mintern J.D., Hubert F.X., Hurt A.C., Besra G.S., Porcelli S., Barr I.G., Doherty P.C., Godfrey D.I., and Turner S.J. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci U S A 106 (2009) 3330-3335
57. Galli G., Nuti S., Tavarini S., Galli-Stampino L., De Lalla C., Casorati G., Dellabona P., and Abrignani S. Innate immune responses support adaptive immunity: NKT cells induce B cell activation. Vaccine 21 Suppl 2 (2003) S48-54
58. Galli G., Pittoni P., Tonti E., Malzone C., Uematsu Y., Tortoli M., Maione D., Volpini G., Finco O., Nuti S., et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A 104 (2007) 3984-3989
59. Tonti E., Galli G., Malzone C., Abrignani S., Casorati G., and Dellabona P. NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood 113 (2009) 370-376
60. Kamath A.T., Rochat A.F., Valenti M.P., Agger E.M., Lingnau K., Andersen P., Lambert P.H., and Siegrist C.A. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PLoS ONE 3 (2008) e3683
61. Werninghaus K., Babiak A., Gross O., Holscher C., Dietrich H., Agger E.M., Mages J., Mocsai A., Schoenen H., Finger K., et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med 206 (2009) 89-97. This study shows that the adjuvant effect of mycobacterial lipids TDB and TDM depends on direct activation of APC through the FcγR-Syk-Card9-Bcl10-Malt1 pathway.
62. LeibundGut-Landmann S., Gross O., Robinson M.J., Osorio F., Slack E.C., Tsoni S.V., Schweighoffer E., Tybulewicz V., Brown G.D., Ruland J., et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 8 (2007) 630-638
63. Leibundgut-Landmann S., Osorio F., Brown G.D., and Reis e Sousa C. Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood 112 (2008) 4971-4980
64. Ng G., Sharma K., Ward S.M., Desrosiers M.D., Stephens L.A., Schoel W.M., Li T., Lowell C.A., Ling C.C., Amrein M.W., et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 29 (2008) 807-818. A surprising conclusion of this work is that MSU crystals bind to DC through membrane cholesterol with a receptor-independent mechanism that requires syk activation.
65. Burgdorf S., Kautz A., Bohnert V., Knolle P.A., and Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316 (2007) 612-616
66. Burgdorf S., Scholz C., Kautz A., Tampe R., and Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 9 (2008) 558-566
67. Sancho D., Mourao-Sa D., Joffre O.P., Schulz O., Rogers N.C., Pennington D.J., Carlyle J.R., and Reis e Sousa C. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 118 (2008) 2098-2110
68. Drane D., Gittleson C., Boyle J., and Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 6 (2007) 761-772
69. Schnurr M., Orban M., Robson N.C., Shin A., Braley H., Airey D., Cebon J., Maraskovsky E., and Endres S. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol 182 (2009) 1253-1259